Clinical Trials
VRC Clinical Trials |
VRC
Home |
ARCHIVE OF VRC CLINICAL
TRIALS
STUDIES
CLOSED TO ACCRUAL
These studies are
recruiting.
VRC Clinical Trials
Related to Development of Vaccines for Prevention of HIV
VRC 001 (01-I-0079):
"Evaluation
of an HIV-1 DNA Vaccine Encoding a Modified Gag-Pol Protein
in Uninfected Adult Volunteers"
VRC 004 (03-I-0022):
A
Phase I Clinical Trial to Evaluate the Safety and Immunogenicity
of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP,
in Uninfected Adult Volunteers
VRC 006 (04-I-0172):
A
Phase I Clinical Trial to Evaluate the Safety and Immunogenicity
of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine,
VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers
VRC 007 (04-I-0254):
A
Phase I Clinical Trial to Evaluate the Safety and Immunogenicity
of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP,
in Uninfected Adult Volunteers
VRC 008 (05-I-0148):
A
Phase I Clinical Trial of a Prime-Boost HIV-1 Vaccination
Schedule: Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, Followed
by Multiclade Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP,
in Uninfected Adult Volunteers
VRC 009 (05-I-0081):
A
Phase I Clinical Trial to Evaluate the Safety and Immunogenicity
of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral
Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects
who were Previously Immunized with VRC-HIVDNA009-00-VP in
VRC 004 (03-I-0022)
VRC 010 (05-I-0140):
A
Phase I Clinical Trial to Evaluate the Safety and Immunogenicity
of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral
Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects
who were Previously Immunized with VRC-HIVDNA016-00-VP in
VRC 007 (04-I-0254)
VRC 011 (06-I-0149):
A
Phase I Clinical Trial of Intramuscular, Subcutaneous and
Intradermal Administration of an HIV-1 Multiclade DNA Vaccine,
VRC-HIVDNA016-00-VP, and an HIV-1 Multiclade Adenoviral Vector
Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers
VRC Clinical Trials
Related to Development of Vaccines for Treatment of HIV
VRC 101 (06-I-0056):
A
Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity
of a Prime-Boost Vaccination Schedule of a Multiclade HIV-1
DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, followed by a Recombinant
Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP,
in HIV-Infected Adult Volunteers
VRC Clinical Trials Related
to Vaccines for Biodefense and Emerging Pathogens
Smallpox Vaccine
Studies
VRC 201 (02-I-0316):
A
Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara
(MVA) to Evaluate its Safety, Dosing Schedule, Immunogenicity
and Protective Efficacy Against Dryvax Challenge in Vaccinia-Naive
Individuals
VRC 203 (03-I-0087):
A
Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara
(MVA) to Evaluate its Safety, Immunogenicity and Protective
Efficacy Against Dryvax Challenge in Vaccinia-Immune Individuals
Ebola Vaccine Studies
VRC 204 (04-I-0028):
A
Phase I Clinical Trial to Evaluate the Safety and Immunogenicity
of a Multiple Strain Ebola DNA Plasmid Vaccine, VRC-EBODNA012-00-VP,
in Adult Volunteers
SARS Vaccine Studies
VRC 301 (05-I-0056):
A
Phase I Study of the Safety and Immunogenicity of a SARS Recombinant
DNA Plasmid Vaccine, VRC-SRSDNA015-00-VP, in Healthy Adult
Volunteers
West Nile Virus
Vaccine Studies
VRC 302 (05-I-0126):
A
Phase I Study of the Safety and Immunogenicity of a West Nile
Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA017-00-VP,
in Healthy Adult Volunteers
VRC 303 (06-I-0110):
A
Phase I Study of the Safety and Immunogenicity of a West Nile
Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP,
in Healthy Adult Subjects
Influenza Vaccine
Studies
VRC 304 (07-I-0042):
A
Phase I Study of the Safety and Immunogenicity of a Recombinant
DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP), Encoding for the
Influenza Virus H5 Hemagglutinin Protein in Healthy Adults
VRC 305 (07-I-0172):
A
Phase I Open-Label Study of the Safety and Immunogenicity
of a Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP,
Encoding for the Influenza Virus H5 Hemagglutinin Protein
Administered Intradermally in Healthy Adults
|